Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress

Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress aXess graft demonstrated excellent patency

Related Keywords

Portugal ,United States ,Porto ,Italy ,Netherlands ,Amber Fennell Chris Welsh ,Eliane Schutte ,Matteo Tozzi ,Alexander Goemans ,Davita Venture Group ,Consilium Strategic Communications ,Vascular Access Society Congress ,Life Sciences ,Pharma Group ,University Of Insubria ,Vascular Access Society In Porto ,Vascular Access Society ,Vascular Surgery ,Xess Vascular Graft ,Kidney Disease ,Kurma Partners ,Ysios Capital ,Grand Pharma Group ,Exeltis ,Presents ,Excellent ,Month ,First ,Human ,Data ,Rom ,Foxess ,Hemodialysis ,Ascular ,Craft ,Trial ,Access ,Society ,Congress ,